Novartis has reported a 28.5% reduced risk of breast cancer recurrence in an updated analysis from the Phase III NATALEE trial of Kisqali (ribociclib), when combined with endocrine therapy.

The US regulator is to hasten development of Novartis’ Kisqali in premenopausal women with a certain form of advanced breast cancer, potentially giving it an edge over Pfizer's first-to-market ...

NICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England and Wales, three months after rejecting it on cost grounds, via the ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

While it can be more difficult to get approved for certain premium cards with a credit score of 600 or below, solid credit card options are still available. We’ve done the research, and these ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Below, Select looks at what it means to have a 600 credit score and the types of credit cards you'd be able to qualify for with it. According to FICO® Score, 15.5% of the population has a credit ...

The Olympus E-600 digital SLR is a lower-cost version of the existing E-620 model which launched in February 2009, with just a couple of changes made to reduce the cost and help provide ...